Higher genetically predicted plasma caffeine concentrations linked to lower risk for type 2 diabetes, with 43 percent of effect mediated by BMI<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 15, 2023 (HealthDay News) — There is a causal association for plasma caffeine concentrations with adiposity and risk for type 2 diabetes, according to a study published online March 14 in BMJ Medicine<\/em>.<\/p>\n Susanna C. Larsson, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a two-sample Mendelian randomization study using genome-wide association study summary data for two single nucleotide polymorphisms associated with plasma caffeine at the genome-wide significance threshold and their association with outcomes among individuals of European ancestry.<\/p>\n The researchers found that higher genetically predicted plasma caffeine concentrations were associated with lower body mass index (beta, \u00e2\u0088\u00920.08 standard deviation [SD], where 1 SD equals about 4.8 kg\/m2<\/sup> in body mass index, for every SD increase in plasma caffeine) and whole-body fat mass (beta, \u00e2\u0088\u00920.06 SD, where 1 SD equals about 9.5 kg), but not fat-free mass. In two consortia, higher genetically predicted plasma caffeine concentrations were associated with a lower risk for type 2 diabetes (combined odds ratio, 0.81). Overall, 43 percent of the effect of caffeine on type 2 diabetes was estimated to be mediated via the reduction in body mass index. Genetically predicted plasma caffeine concentrations were not strongly associated with a risk for any of the studied cardiovascular diseases.<\/p>\n “This mendelian randomization study found evidence to support causal associations of higher plasma caffeine concentrations with lower adiposity and risk of type 2 diabetes,” the authors write. “Randomized controlled trials are warranted to assess whether noncaloric caffeine containing beverages might play a role in reducing the risk of obesity and type 2 diabetes.”<\/p>\n One author disclosed financial ties to Novo Nordisk.<\/p>\n